ReviewLipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention
Introduction
Despite the inconsistent or weak association between cholesterol and stroke, a decrease in cholesterol concentrations with statins can reduce the incidence of stroke in high-risk populations1 and in patients with a stroke or transient ischaemic attack.2 Statin therapy has become the most important advance in stroke prevention since the introduction of aspirin and blood pressure-lowering therapies. In combination with other preventive strategies, such as blood pressure-lowering and antithrombotic treatment, a 1 mmol/L decrease in LDL cholesterol concentrations can substantially decrease stroke incidence.1 Statins not only lower the overall risk of stroke but also slow the progression of carotid atherosclerosis,3 reduce inflammation and endothelial dysfunction, decrease platelet aggregation to improve fibrinolysis, lower blood pressure, and decrease the risk of thromboembolic complications to the brain by reducing the incidence of myocardial infarction. Statins might also have a neuroprotective effect.4, 5, 6 Other lipid-modifying drugs have been less successful in reducing the incidence of stroke;7, 8 however, because of the strong rationale for use of triglyceride-lowering drugs and treatments that raise concentrations of HDL cholesterol in patients with stroke, further investigation of these possible treatments is needed. In this Review, we outline the epidemiology of lipids and risk of stroke and discuss the evidence for decreasing lipid concentrations in patients who are at high risk of stroke or have had a previous stroke. Finally, we offer suggestions for possible avenues for future research.
Section snippets
Lipids and stroke
The Prospective Study Collaboration group did a meta-analysis of data from 45 observational cohorts that included 450 000 individuals,9 in which 13 397 fatal strokes were reported during an average follow-up of 16 years. No association between total cholesterol concentration and risk of fatal stroke was found. In a further meta-analysis of almost 1 million individuals, the collaboration found a clear association between total serum concentration of cholesterol and risk of fatal myocardial
Search strategy and selection criteria
For this Review, we updated our previous meta-analysis, which identified references from January, 1966, to August, 2003. References for this Review were similarly identified through searches of PubMed (from September, 2003, to December, 2008) for studies of statins with the search terms “pravastatin”, “lovastatin”, “atorvastatin”, “simvastatin”, “fluvastatin”, “cerivastatin”, “rosuvastatin”, “pitavastatin”, “HMG-CoA reductase inhibitor”, and “statin”. The search was restricted to trials in
High-risk patients
We identified statin trials that included 165 792 individuals at high risk of stroke (table).28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 Incidence of all strokes was reduced by 18% (95% CI 13–23%, p<0·0001; figure 1), incidence of fatal stroke was reduced by 13% (−3 to 27, p=0·10; figure 2), although this did not reach statistical significance, and incidence of haemorrhagic stroke did not increase (RR 1·03, 95% CI 0·75–1·41, p=0·88; figure 3),
Intense reduction of LDL concentrations to target versus statin treatment
The latest recommendations for primary prevention of stroke from the European Stroke Organisation are that blood cholesterol should be checked regularly; high cholesterol (eg, LDL cholesterol >3·9 mmol/L [150 mg/dL]) should be managed with lifestyle modification (class IV, level C) and a statin (class I, level A). In secondary prevention of stroke, statin therapy is recommended for patients with non-cardioembolic stroke (class I, level A).59
These recommendations, which are based on expert
Conclusions
The relation between total and LDL cholesterol and stroke risk is inconsistent or weak. This inconsistency might be because of several reasons: many studies investigate total cholesterol, whereas different cholesterol components have different effects; studies typically look at total stroke, and different causes might be differently affected by cholesterol; and competing risk of death from other cardiovascular causes could further attenuate the relation between stroke (and fatal stroke in
References (62)
- et al.
Stroke prevention, blood cholesterol, and statins
Lancet Neurol
(2004) - et al.
The paradox of cholesterol and stroke
Lancet
(2007) - et al.
High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review
Atherosclerosis
(2008) - et al.
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
Lancet
(2004) - et al.
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
Lancet
(2003) - et al.
Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial
Lancet
(2006) - et al.
Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study
J Am Coll Cardiol
(2004) - et al.
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
Lancet
(2004) - et al.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT–LLA): a multicentre randomised controlled trial
Lancet
(2003) - et al.
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Lancet
(2002)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
Lancet
High-dose atorvastatin after stroke or transient ischemic attack
N Engl J Med
Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis
Stroke
The dynamics of statins: from event prevention to neuroprotection
Stroke
Placebo-controlled trial of high-dose atorvastatin in patients with severe cerebral small vessel disease
Stroke
Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor
Circulation
Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT)
Circulation
Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts
Lancet
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths
Lancet
Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study
Stroke
Lipid lowering and recurrent stroke: another stroke paradox?
Eur Heart J
Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial
N Engl J Med
Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study
BMJ
LDL Cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study
Stroke
Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial
Atherosclerosis
Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies
Atherosclerosis
Nonfasting triglycerides and risk of ischemic stroke in the general population
JAMA
Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease
Eur Heart J
Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study
J Intern Med
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
N Engl J Med
Rosuvastatin in older patients with systolic heart failure
N Engl J Med
Cited by (526)
Medium-intensity statin with ezetimibe versus high-intensity statin in acute ischemic cerebrovascular disease (MESIA): A randomized clinical trial
2024, Journal of Stroke and Cerebrovascular DiseasesGuideline-Directed Low-Density Lipoprotein Cholesterol Management After Acute Ischemic Stroke: Findings from a National Health Care Service
2023, American Journal of Cardiology